Balanced news tone
News Sentiment
GRFS sentiment intelligence
Grifols SA ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
54
Balanced news tone
48 relevant articles
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+1.5% over one week, -3.6% over four weeks, trend inactive, and near fair-value range.
Grifols stock steadies on its plasma business model
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
78/100 classification
One-week reaction
1.5%
Price digesting
Trend fit
Trend inactive
-3.6% over four weeks
Fair value
-12.8%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
13
Neutral
33
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
ad-hoc-news.de
Direct company coverage
Grifols stock steadies on its plasma business model
Grifols' stock performance is primarily driven by its plasma-derived therapies business model, focusing on immunoglobulins, albumin, and other specialty medicines. The company's success relies on efficient plasma collection, fractionation, and long-cycle production, rather than s
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 11:10
- Source
- ad-hoc-news.de
DirectorsTalk Interviews
Direct company coverage
Grifols, S.A. (GRFS) Stock Analysis: Exploring a Potential 49.45% Upside for Healthcare Investors
Grifols, S.A. (GRFS), a Spanish pharmaceutical company specializing in plasma-derived medicines, is showing a potential upside of 49.45% despite recent revenue declines. Trading at $7.27 USD with a market capitalization of $4.95 billion, the stock has a low forward P/E ratio of 5
- Tone
- Positive 69/100
- Event
- Earnings
- Published
- 13 Jul 2026 09:12
- Source
- DirectorsTalk Interviews
ad-hoc-news.de
Direct company coverage
Grifols stock holds steady as investors weigh the business mix
Grifols, a Spanish company specializing in plasma-derived medicines, diagnostics, and hospital products, is maintaining a steady stock performance as investors evaluate its diverse business model. The company's focus on therapies from human plasma provides a defensive profile, th
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 01:39
- Source
- ad-hoc-news.de
ad-hoc-news.de
Direct company coverage
Grifols stock reflects a complex plasma business amid global healthcare demand
Grifols S.A. stock offers exposure to the specialized global market for plasma-derived medicines, built on a network of plasma collection centers, advanced fractionation plants, and a diverse portfolio of treatments for chronic and acute conditions. The company's business model r
- Tone
- Positive 74/100
- Event
- Macro sensitivity
- Published
- 11 Jul 2026 08:23
- Source
- ad-hoc-news.de
TradingView
Direct company coverage
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks
This article provides a list of actively and passively managed ETFs that hold Grifols, S.A. Sponsored ADR Class B stocks. The ETFs are sorted by their market value of Grifols holdings and include details such as issuer, management style, focus, expense ratio, assets under managem
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 17:10
- Source
- TradingView
Ad Hoc News
Direct company coverage
Grifols stock holds steady as plasma specialist refines its business model
Grifols stock shows a company transforming as the plasma specialist prioritizes debt reduction and operational improvements to fuel long-term expansion. The company, a global leader in plasma-derived medicines, is focusing on financial discipline, portfolio optimization, and effi
- Tone
- Positive 67/100
- Event
- Balance sheet
- Published
- 10 Jul 2026 12:41
- Source
- Ad Hoc News
Ad-hoc-news.de
Direct company coverage
Grifols SA outlines plasma strategy as investors weigh long-term growth
Grifols SA, a global leader in plasma-derived medicines, is focusing on refining its collection and manufacturing operations while addressing investor concerns about balance sheet discipline and demand for immunology treatments. The company's strategy involves improving efficienc
- Tone
- Positive 71/100
- Event
- Macro sensitivity
- Published
- 09 Jul 2026 14:31
- Source
- Ad-hoc-news.de
Ad-hoc-news.de
Direct company coverage
Grifols navigates plasma demand and debt strategy as global healthcare needs grow
Grifols S.A. is managing the complex interplay of plasma supply, debt reduction, and regulatory oversight, crucial for providing therapies for immune and neurological conditions worldwide. The company is focused on strengthening investor confidence through transparent communicati
- Tone
- Neutral 50/100
- Event
- Macro sensitivity
- Published
- 09 Jul 2026 10:10
- Source
- Ad-hoc-news.de
TradingView
Direct company coverage
G0FB Forecast — Price Target — Prediction for 2027
This page provides forecast and price target information for Grifols, S.A. Sponsored ADR Class B (G0FB). It indicates a price target of 12.32 based on analyst forecasts and includes sections for analyst ratings, EPS, and revenue metrics.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 Jul 2026 23:09
- Source
- TradingView
AD HOC NEWS
Direct company coverage
Grifols strengthens its plasma-based therapies. Investors watch the long-term growth story
Grifols S.A. is expanding its global plasma business and specialty therapies, focusing on plasma-derived medicines and diagnostics. The company's strategy involves investments in plasma collection, diversified diagnostics, and bioscience services, aiming for long-term growth whil
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 08 Jul 2026 08:06
- Source
- AD HOC NEWS
TradingView
Direct company coverage
Price to earnings forward of Grifols, S.A. Class A – BME:GRF
This article displays the "Price to earnings forward" financial metric for Grifols, S.A. Class A (BME:GRF) on TradingView. It shows that there are no trades and the market is closed for this specific data point, which is made by humans. The content is primarily a data placeholder
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 Jul 2026 07:13
- Source
- TradingView
TradingView
Direct company coverage
ETFs Investing in Grifols, S.A. Class A Stocks
This article lists various Exchange Traded Funds (ETFs) that hold Grifols, S.A. Class A stocks. It provides a detailed table including each fund's market value, weight of Grifols stock, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 11:44
- Source
- TradingView
DirectorsTalk Interviews
Direct company coverage
Grifols, S.A. (GRFS) Stock Analysis: A 51.75% Upside Potential In The Healthcare Sector
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 Jul 2026 09:24
- Source
- DirectorsTalk Interviews
TradingView
Direct company coverage
Price to earnings forward of Grifols, S.A. Class A – VIE:GRF
This article provides the "Price to earnings forward" metric for Grifols, S.A. Class A (VIE:GRF) on the Vienna Stock Exchange. It indicates that the market was closed with no trades recorded for this particular metric. The content primarily focuses on financial data for the pharm
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Jul 2026 02:40
- Source
- TradingView
AD HOC NEWS
Direct company coverage
Grifols S.A. highlights plasma leadership as investors assess long-term strategy
Grifols S.A. is maintaining its strong position in the global plasma-based medicines market, with investors closely evaluating its long-term strategy and financial health. The company, known for its extensive plasma collection network and complex fractionation facilities, focuses
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 05 Jul 2026 07:39
- Source
- AD HOC NEWS
TradingView
Direct company coverage
A2ABZN Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Grifols, S.A. Pref Class B (A2ABZN) stock, outlining analysts' expectations for its future price. It also covers the stock's current price, historical performance, market capitalization, and financial data including revenue, n
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jul 2026 21:10
- Source
- TradingView
Ad-hoc-news.de
Direct company coverage
Grifols stock holds its line. Investors watch the next filing.
Grifols stock is holding steady, with investors focusing on the company's business fundamentals and upcoming filings rather than new headlines. The Spanish plasma products group, Grifols S.A. (ISIN ES0171996087), operates a plasma collection and processing model, making cash gene
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 04 Jul 2026 11:09
- Source
- Ad-hoc-news.de
Finviz
Direct company coverage
GRFS - Grifols SA ADR Short Interest
This article provides a detailed overview of Grifols SA ADR (GRFS) stock, focusing on its short interest and various financial metrics. It includes data on market capitalization, income, sales, dividends, P/E ratio, EPS growth, insider and institutional ownership, profitability m
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jul 2026 10:09
- Source
- Finviz
Finviz
Direct company coverage
GRFS - Grifols SA ADR Volatility & Greeks
This article provides a comprehensive financial overview of Grifols SA ADR (GRFS), detailing its stock performance, volatility, and key financial ratios. It includes data on market capitalization, income, sales, dividend information, and analyst recommendations. The report also h
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 03 Jul 2026 23:40
- Source
- Finviz
Ad-hoc-news.de
Direct company coverage
Grifols steady as plasma business underpins long-term growth
Grifols S.A. relies on its global plasma-derivatives franchise and diversified product portfolio for long-term growth, despite ongoing balance sheet priorities and evolving market regulations. The company's core business, plasma-derived therapies, drives most revenue and benefits
- Tone
- Positive 63/100
- Event
- Earnings
- Published
- 03 Jul 2026 15:40
- Source
- Ad-hoc-news.de
Finviz
Direct company coverage
GRFS - Grifols SA ADR Latest SEC Filings
This article provides comprehensive financial data and performance metrics for Grifols SA ADR (GRFS). It covers key financial figures like market cap, income, sales, and various ratios, along with stock performance metrics, insider ownership, analyst recommendations, and recent S
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 03 Jul 2026 14:39
- Source
- Finviz
Ad-hoc-news.de
Direct company coverage
Grifols focuses on plasma-based therapies as investors assess long-term growth
Grifols S.A. is a global healthcare group specializing in plasma-derived medicines, with a business model centered on a stable network of plasma donation centers, strict quality controls, and compliance. The company's long-term growth is driven by increasing demand for specialty
- Tone
- Positive 65/100
- Event
- Macro sensitivity
- Published
- 02 Jul 2026 21:13
- Source
- Ad-hoc-news.de
Finviz
Direct company coverage
GRFS - Grifols SA ADR Options
This article provides a detailed financial overview of Grifols SA (GRFS) ADR, including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists performance metrics, insider ownership, institutional ownership, and short interest da
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 18:39
- Source
- Finviz
Finviz
Direct company coverage
GRFS - Grifols SA ADR Forecast, Target Price
This article provides a detailed financial overview and forecast for Grifols SA ADR (GRFS), including key financial metrics, performance indicators, and analyst target prices. It highlights the company's current stock price, dividend information, various valuation ratios, and per
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 02 Jul 2026 14:39
- Source
- Finviz
TradingView
Direct company coverage
Price to earnings forward of Grifols, S.A. Class A – BX:OZTA
This article displays financial data for Grifols, S.A. Class A (BX:OZTA), specifically its price-to-earnings forward ratio. The content primarily consists of navigation and technical details from the TradingView platform, with limited substantive financial information presented i
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Jun 2026 11:10
- Source
- TradingView
TradingView
Direct company coverage
G0F Forecast — Price Target — Prediction for 2027
This TradingView page provides forecast information, price targets, and analyst ratings for Grifols, S.A. Sponsored ADR Class A (G0F) on the Munich Stock Exchange. It includes sections for actuals and estimates for EPS and revenue, along with a disclaimer stating it is not invest
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 10:39
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Grifols, S.A. Class A – EUROTLX:4GRF
The article focuses on the "Price to sales forward" financial metric for Grifols, S.A. Class A (4GRF) on the EUROTLX exchange, as presented on TradingView. It indicates that no specific value or change information is currently available for this metric. The content largely compri
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 20:10
- Source
- TradingView
TradingView
Direct company coverage
GRFS Forecast — Price Target — Prediction for 2027
This page provides a forecast and price target for Grifols, S.A. (GRFS) for the year 2027. It indicates a price target of 14.43 based on one analyst's forecast and also includes information on analyst ratings, EPS, and revenue metrics.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 12:10
- Source
- TradingView
TradingView
Direct company coverage
Grifols, S.A. Class A Actuals & Estimates (EUROTLX:4GRF)
This article provides financial actuals and estimates for Grifols, S.A. Class A (4GRF) traded on EUROTLX, covering income statement, balance sheet, and cash flow. It includes current stock price, historical performance, analyst forecasts, and upcoming earnings dates. The company'
- Tone
- Negative 38/100
- Event
- Earnings
- Published
- 27 Jun 2026 11:39
- Source
- TradingView
TradingView
Direct company coverage
Grifols, S.A. Class A Actuals & Estimates (BME:GRF)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 01:21
- Source
- TradingView